» Articles » PMID: 15226217

Unstable Carotid Plaques Exhibit Raised Matrix Metalloproteinase-8 Activity

Overview
Journal Circulation
Date 2004 Jul 1
PMID 15226217
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The fibrous cap of atherosclerotic plaques is composed predominantly of type I and III collagen. Unstable carotid plaques are characterized by rupture of their cap, leading to thromboembolism and stroke. The proteolytic mechanisms causing plaque disruption are undefined, but the collagenolytic matrix metalloproteinase (MMP) -1, -8, and -13 may be implicated. The aim of this study was to quantify the concentrations of these collagenases in carotid plaques and to determine their relationship to markers of plaque instability.

Methods And Results: Atherosclerotic plaques were collected from 159 patients undergoing carotid endarterectomy. The presence and timing of carotid territory symptoms were ascertained. Preoperative embolization was recorded by transcranial Doppler. Each plaque was assessed for histological features of instability. Plaque MMP concentrations were quantified with ELISA. Significantly higher concentrations of active MMP-8 were observed in the plaques of symptomatic patients (20.5 versus 11.4 ng/g; P=0.0002), in plaques of emboli-positive patients (22.7 versus 13.5 ng/g; P=0.0037), and in those plaques showing histological evidence of rupture (20.8 versus 14.7 ng/g; P=0.0036). No differences were seen in the levels of MMP-1 and MMP-13. Immunohistochemistry, in situ hybridization, and colocalization studies confirmed the presence of MMP-8 protein and mRNA within the plaque, which colocalized with macrophages.

Conclusions: These data suggest that the active form of MMP-8 may be partly responsible for degradation of the collagen cap of atherosclerotic plaques. This enzyme represents an attractive target for drug therapy aimed at stabilizing vulnerable plaques.

Citing Articles

The value of contrast-enhanced ultrasound in assessing carotid plaque vulnerability and predicting stroke risk.

Cao J, Zeng Y, Zhou Y, Yao Z, Tan Z, Huo G Sci Rep. 2025; 15(1):5850.

PMID: 39966491 PMC: 11836186. DOI: 10.1038/s41598-025-90319-2.


Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions.

Mitsis A, Myrianthefs M, Sokratous S, Karmioti G, Kyriakou M, Drakomathioulakis M Biomedicines. 2024; 12(8).

PMID: 39200135 PMC: 11351818. DOI: 10.3390/biomedicines12081670.


Unveiling TIMPs: A Systematic Review of Their Role as Biomarkers in Atherosclerosis and Coronary Artery Disease.

Aminuddin A, Samah N, Vijakumaran U, Che Roos N, Mohd Nor F, Wan Razali W Diseases. 2024; 12(8).

PMID: 39195176 PMC: 11353419. DOI: 10.3390/diseases12080177.


Novel Therapeutic Approaches to Prevent Atherothrombotic Ischemic Stroke in Patients with Carotid Atherosclerosis.

Puig N, Sole A, Aguilera-Simon A, Grinan R, Rotllan N, Camps-Renom P Int J Mol Sci. 2023; 24(18).

PMID: 37762627 PMC: 10531661. DOI: 10.3390/ijms241814325.


Matrix metalloproteinases in coronary artery disease and myocardial infarction.

Brauninger H, Kruger S, Bacmeister L, Nystrom A, Eyerich K, Westermann D Basic Res Cardiol. 2023; 118(1):18.

PMID: 37160529 PMC: 10169894. DOI: 10.1007/s00395-023-00987-2.